JAK inhibitor helping vitiligo? Results from phase 3 TRuE-V trial ruxolitinib cream in adolescent/adult vitiligo pts - showed significantly more RUX pts with 75% improvement in facial vitiligo area scoring index (F-VASI75) compared to control at Week 24 https://t.co/q98CBjfdQi